-
Product Insights
Glutamate Receptor Ionotropic NMDA 2 – Drugs In Development, 2023
Global Markets Direct’s Glutamate Receptor Ionotropic NMDA 2 provides in depth analysis on Glutamate Receptor Ionotropic NMDA 2 targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Glutamate...
-
Product Insights
Glutamate Receptor Ionotropic NMDA 2B – Drugs In Development, 2023
Global Markets Direct’s Glutamate Receptor Ionotropic NMDA 2B provides in depth analysis on Glutamate Receptor Ionotropic NMDA 2B targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Glutamate...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dalzanemdor in Huntington Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dalzanemdor in Huntington Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dalzanemdor in Huntington Disease Drug Details: Dalzanemdor (SAGE-718) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ketamine in Bipolar Disorder (Manic Depression)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ketamine in Bipolar Disorder (Manic Depression) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ketamine in Bipolar Disorder (Manic Depression) Drug Details: Ketamine (NRX-100)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ketamine Hydrochloride PR in Treatment Resistant Depression
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ketamine Hydrochloride PR in Treatment Resistant Depression report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ketamine Hydrochloride PR in Treatment Resistant Depression Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Esketamine in Major Depressive Disorder
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Esketamine in Major Depressive Disorder report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Esketamine in Major Depressive Disorder Drug Details: Esketamine (CLE-100) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Esketamine Hydrochloride in Bipolar Disorder (Manic Depression)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Esketamine Hydrochloride in Bipolar Disorder (Manic Depression) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Esketamine Hydrochloride in Bipolar Disorder (Manic Depression) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Amantadine Hydrochloride in Traumatic Brain Injury
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Amantadine Hydrochloride in Traumatic Brain Injury report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Amantadine Hydrochloride in Traumatic Brain Injury Drug Details: Amantadine hydrochloride...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – XW-10508 in Major Depressive Disorder
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - XW-10508 in Major Depressive Disorder report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. XW-10508 in Major Depressive Disorder Drug Details: XW-10508 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AV-101 in Epilepsy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AV-101 in Epilepsy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AV-101 in Epilepsy Drug Details: AV-101 is under development for the treatment of...